Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
Simon Auer, Alexandra Wojna, Markus Hell
文献索引:Antimicrob. Agents Chemother. 54 , 4006-8, (2010)
全文:HTML全文
摘要
An increase in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiotics fosfomycin, pivmecillinam, and nitrofurantoin and the parenteral antibiotic ertapenem. Susceptibility rates indicate that fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) could be considered important oral treatment options.
相关化合物
相关文献:
2013-10-15
[Tidsskr. Nor. Laegeforen. 133(19) , 2052-6, (2013)]
2005-01-01
[J. Appl. Microbiol. 99(4) , 803-15, (2005)]
2007-03-01
[Scand. J. Prim. Health Care 25(1) , 49-57, (2007)]
2004-01-01
[Scand. J. Infect. Dis. 36(4) , 296-301, (2004)]
2009-03-01
[Antimicrob. Agents Chemother. 53(3) , 912-7, (2009)]